Pharmaceutical intermediates

Delafloxacin meglumine Intermediates

1 pharmaceutical intermediate for Delafloxacin meglumine. Indication: Community-acquired pneumonia; Bacterial skin diseases; Skin and skin structure infections.

提交项目 All intermediates

About Delafloxacin meglumine

Originator: Wakunaga Pharmaceutical Co., Ltd.
Indication: Community-acquired pneumonia; Bacterial skin diseases; Skin and skin structure infections
Approved Date: 06/19/2017
NCE Patent: 06/19/2027
DS/DP: 10/07/2025

Available intermediates

1 intermediate currently listed for Delafloxacin meglumine. Request specifications, documentation or a quotation for any item below.

Delafloxacin meglumine intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
3,5-Difluoropyridine-2,6-diamine	247069-27-8	/	/

Other programs under D

Dabigatran Etexilate Dabigatran etexilate mesylate Dabrafenib Mesylate Dacomitinib Danicopan Dapagliflozin Daridorexant Hydrochloride Darolutamide

Building toward Delafloxacin meglumine?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →